Ani Pharmaceuticals (ANIP) EBT (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 16 years of EBT data on file, last reported at $40.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 101.24% year-over-year to $40.2 million; the trailing twelve-month figure through Mar 2026 stood at $116.0 million (up 520.99% YoY), and the FY2025 full-year result was $95.8 million, up 531.26% from the prior year.
• EBT rose to $40.2 million in Q1 2026, from $31.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $40.2 million in Q1 2026 to a low of -$31.5 million in Q3 2024.
• A 5-year average of $4.2 million and a median of $2.2 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT plunged 34178.95% in 2022 and jumped 1070.21% in 2024, its largest moves.
• Tracing ANIP's EBT over 5 years: stood at -$5.8 million in 2022, then surged by 116.43% to $947000.0 in 2023, then plunged by 1553.22% to -$13.8 million in 2024, then jumped by 328.74% to $31.5 million in 2025, then rose by 27.77% to $40.2 million in 2026.
• Business Quant data shows ANIP's EBT at $40.2 million in Q1 2026, $31.5 million in Q4 2025, and $33.8 million in Q3 2025.